HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:NURS - CA44877L1013 - Common Stock
3.57 CAD
-1.31 (-26.84%)
NURS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 8 industry peers in the Health Care Technology industry. NURS has a great financial health rating, but its profitability evaluates not so good. NURS is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year NURS has reported negative net income.
In the past year NURS had a positive cash flow from operations.
1.2 Ratios
NURS has a better Return On Assets (0.02%) than 87.50% of its industry peers.
The Return On Equity of NURS (0.04%) is better than 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROIC | N/A |
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.01%, NURS belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
NURS has a Gross Margin of 34.30%. This is comparable to the rest of the industry: NURS outperforms 50.00% of its industry peers.
In the last couple of years the Gross Margin of NURS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.01% | ||
| GM | 34.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NURS does not have a ROIC to compare to the WACC, probably because it is not profitable.
NURS has more shares outstanding than it did 1 year ago.
There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
NURS has an Altman-Z score of 27.59. This indicates that NURS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.59, NURS is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 27.59 |
ROIC/WACCN/A
WACC9.26%
2.3 Liquidity
NURS has a Current Ratio of 1.49. This is a normal value and indicates that NURS is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.49, NURS is doing good in the industry, outperforming 62.50% of the companies in the same industry.
A Quick Ratio of 1.49 indicates that NURS should not have too much problems paying its short term obligations.
NURS's Quick ratio of 1.49 is fine compared to the rest of the industry. NURS outperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.49 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
NURS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.54%, which is quite impressive.
The Revenue has grown by 32.60% in the past year. This is a very strong growth!
The Revenue has been growing by 137.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)99.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.14%
Revenue 1Y (TTM)32.6%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%79.24%
3.2 Future
The Earnings Per Share is expected to grow by 279.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, NURS will show a very strong growth in Revenue. The Revenue will grow by 121.25% on average per year.
EPS Next Y974.04%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue Next Year223.76%
Revenue Next 2Y174.11%
Revenue Next 3Y121.25%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
NURS is valuated correctly with a Price/Forward Earnings ratio of 12.62.
NURS's Price/Forward Earnings ratio is rather cheap when compared to the industry. NURS is cheaper than 100.00% of the companies in the same industry.
NURS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.62 |
4.2 Price Multiples
NURS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NURS is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2097.59 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NURS's earnings are expected to grow with 279.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y440.3%
EPS Next 3Y279.01%
5. Dividend
5.1 Amount
NURS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NURS (11/28/2025, 7:00:00 PM)
3.57
-1.31 (-26.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners0.28%
Inst Owner ChangeN/A
Ins Owners2.14%
Ins Owner ChangeN/A
Market Cap168.90M
Revenue(TTM)18.48M
Net Income(TTM)1.50K
Analysts80
Price Target8.67 (142.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)12.5%
Revenue NQ rev (1m)-12.58%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.48%
Revenue NY rev (3m)-11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.62 | ||
| P/S | 9.12 | ||
| P/FCF | N/A | ||
| P/OCF | 148.01 | ||
| P/B | 49.36 | ||
| P/tB | 117.42 | ||
| EV/EBITDA | 2097.59 |
EPS(TTM)0
EYN/A
EPS(NY)0.28
Fwd EY7.92%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.02
OCFY0.68%
SpS0.39
BVpS0.07
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.01% | ||
| GM | 34.3% | ||
| FCFM | N/A |
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score6
Asset Turnover2.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 575.04% | ||
| Cap/Sales | 7.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1065.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.49 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z | 27.59 |
F-Score6
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.14%
EPS Next Y974.04%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue 1Y (TTM)32.6%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%79.24%
Revenue Next Year223.76%
Revenue Next 2Y174.11%
Revenue Next 3Y121.25%
Revenue Next 5YN/A
EBIT growth 1Y92.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1245.74%
EBIT Next 3Y347.79%
EBIT Next 5YN/A
FCF growth 1Y17.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y384.63%
OCF growth 3YN/A
OCF growth 5YN/A
HYDREIGHT TECHNOLOGIES INC / NURS.CA FAQ
Can you provide the ChartMill fundamental rating for HYDREIGHT TECHNOLOGIES INC?
ChartMill assigns a fundamental rating of 5 / 10 to NURS.CA.
What is the valuation status for NURS stock?
ChartMill assigns a valuation rating of 4 / 10 to HYDREIGHT TECHNOLOGIES INC (NURS.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for HYDREIGHT TECHNOLOGIES INC?
HYDREIGHT TECHNOLOGIES INC (NURS.CA) has a profitability rating of 3 / 10.
Can you provide the financial health for NURS stock?
The financial health rating of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is 7 / 10.
What is the expected EPS growth for HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?
The Earnings per Share (EPS) of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is expected to grow by 974.04% in the next year.